产品
编 号：F752854
产品类型
规格
价格
是否有货
结构图
CAS No: 2449086-91-1
产品详情
生物活性：
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model.
体内研究：
Ormutivimab (20 IU/kg；肌肉注射；单剂量) 保护比格犬免受 RABV BD06 的致命攻击。Ormutivimab (20 IU/kg、100 IU/kg；肌注；单剂量) 保护受攻击的 Kunming 小鼠免受各种狂犬病病毒的侵害。Animal Model:Balb/c mice challenge model with rabies virus
Dosage:20 IU/kg, 100 IU/kg
Administration:Intramuscular injection; single dose after 4 hr after infection
Result:Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model.
体内研究：
Ormutivimab (20 IU/kg；肌肉注射；单剂量) 保护比格犬免受 RABV BD06 的致命攻击。Ormutivimab (20 IU/kg、100 IU/kg；肌注；单剂量) 保护受攻击的 Kunming 小鼠免受各种狂犬病病毒的侵害。Animal Model:Balb/c mice challenge model with rabies virus
Dosage:20 IU/kg, 100 IU/kg
Administration:Intramuscular injection; single dose after 4 hr after infection
Result:Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备